8-K: LivaNova Exceeds Expectations with Strong First Quarter, Raises Full-Year Guidance

LivaNova reported a strong first quarter with double-digit revenue growth and increased its full-year revenue and earnings per share guidance.

Summary

• LivaNova PLC announced its financial results for the first quarter of 2024, showing a 12.0% increase in revenue on a reported basis, reaching $294.9 million.
• On a constant-currency basis, revenue increased by 12.4%, and excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue grew by 13.5%.
• The company reported a U.S. GAAP diluted loss per share of $0.78, but an adjusted diluted earnings per share of $0.73.
• LivaNova closed a private offering of $345.0 million in convertible senior notes and repurchased $230.0 million in exchangeable senior notes.
• The company also achieved a positive predictive outcome in the OSPREY clinical study for obstructive sleep apnea and completed enrollment.
• The Cardiopulmonary segment saw a 14.8% increase in revenue on a reported basis and 15.7% on a constant-currency basis, driven by Essenz Perfusion System sales and strong consumables demand.
• The Neuromodulation segment experienced a 10.9% increase in revenue on a reported basis and 11.0% on a constant-currency basis, with double-digit growth in the U.S. and Rest of World regions.
• Adjusted operating income for the quarter was $53.1 million, compared to $26.8 million in the same period last year.
• LivaNova has raised its full-year 2024 revenue growth guidance to between 6% and 7% on a constant-currency basis, or 8% to 9% excluding the ACS segment wind down.
• Adjusted diluted earnings per share for 2024 are now expected to be in the range of $3.05 to $3.15, with an estimated 55 million shares outstanding.
• The company continues to estimate adjusted free cash flow for 2024 to be between $95 and $115 million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, increased guidance, and successful debt refinancing. The positive clinical trial results also contribute to the optimistic outlook. However, the GAAP loss per share and the wind down of the ACS segment temper the overall sentiment slightly.

Positives

• LivaNova achieved double-digit revenue growth in both the Cardiopulmonary and Neuromodulation segments.
• The company has raised its full-year revenue and adjusted diluted earnings per share guidance.
• The Essenz Perfusion System is driving growth in the Cardiopulmonary segment.
• The company has successfully completed a significant debt refinancing.
• The OSPREY clinical study showed positive results, indicating potential for future product success.

Negatives

• The company reported a U.S. GAAP diluted loss per share of $0.78 for the quarter.
• The Advanced Circulatory Support (ACS) segment is being wound down, which has a negative impact on reported revenue.
• Foreign currency is expected to be a 1% headwind for the full year.

Risks

• The company faces risks related to global market volatility, economic conditions, and foreign exchange fluctuations.
• Cyber-attacks and disruptions to IT systems pose a risk to operations.
• There are risks associated with supply chain pressures and changes in technology.
• The company faces risks related to obtaining regulatory approvals and reimbursement for its products.
• There are risks related to product liability claims and legal proceedings, including the 3T Heater-Cooler and SNIA litigations.
• The company is exposed to risks related to environmental laws and regulations.
• Failure to retain key personnel and manage labor costs could impact performance.
• The company faces risks related to the impact of climate change and ESG pressures.

Future Outlook

LivaNova has raised its full-year 2024 revenue growth guidance to between 6% and 7% on a constant-currency basis, or 8% to 9% excluding the ACS segment wind down. Adjusted diluted earnings per share for 2024 are now expected to be in the range of $3.05 to $3.15. The company continues to estimate adjusted free cash flow for 2024 to be between $95 and $115 million.

Management Comments

• In the first quarter, LivaNova achieved double-digit revenue and operating income growth in both the Cardiopulmonary and Neuromodulation segments, said Vladimir Makatsaria, Chief Executive Officer of LivaNova.
• Looking ahead, our priorities continue to emphasize execution, innovation and talent development.
• We are confident that by delivering in each of these areas, we will improve patient outcomes and create shareholder value.

Industry Context

LivaNova's strong performance in the first quarter reflects a positive trend in the medical technology sector, particularly in the Cardiopulmonary and Neuromodulation segments. The company's focus on innovation and strategic execution aligns with industry best practices, and the positive results from the OSPREY study could position them well in the sleep apnea market.

Comparison to Industry Standards

• LivaNova's 12% revenue growth is strong compared to some of its peers in the medical device industry, such as Medtronic and Abbott, which have reported more modest growth in recent quarters.
• The 15.7% constant-currency growth in the Cardiopulmonary segment is particularly impressive, indicating strong demand for their Essenz Perfusion System, which is a key differentiator.
• The adjusted diluted EPS of $0.73 is a significant improvement year-over-year, suggesting effective cost management and operational efficiency.
• The successful debt refinancing and positive clinical trial results are also positive indicators compared to industry benchmarks.

Legal Proceedings

• The company is involved in ongoing litigation related to the 3T Heater-Cooler and SNIA matters.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and earnings guidance.
• Employees are recognized for their contributions to the company's success.
• Customers will benefit from the company's focus on innovation and improved patient outcomes.
• The company's financial stability is strengthened by the debt refinancing.

Next Steps

• The company will continue to focus on execution, innovation, and talent development.
• LivaNova will host a business update conference call and webcast on May 1, 2024, to discuss the financial results.

Key Dates

Keywords

LivaNova, Cardiopulmonary, Neuromodulation, Revenue, Earnings Per Share, Medical Technology, Financial Results, Guidance, OSPREY Study, Convertible Notes